Synopsis covers ADA update on pharmaceutical management of type 2 diabetes
Experts summarized the latest guidance on medication therapy from the American Diabetes Association (ADA) in a recent article.
A synopsis, published by Annals of Internal Medicine on Sept. 1, reviewed recommendations on pharmacologic approaches to glycemic treatment from the latest version of the American Diabetes Association (ADA) Standards of Medical Care in Diabetes.
Experts from Mark's Hospital and St. Mark's Diabetes Center in Salt Lake City summarized the guidelines, which were developed by the ADA Professional Practice Committee. They noted that early combination therapy is recommended when glycemic control is not achieved within three months or patients have cardiovascular disease or chronic kidney disease and type 2 diabetes. Metformin is still the preferred initial pharmacologic agent. The guidelines were published by Diabetes Care in January.